5. Limitations
We acknowledge certain limitations within our study. First, extracted/calculated HRs were not adjusted for confounders. Secondly, there were differences in follow-up times with 3 and 2 studies that followed patients up to 12 and 24 months, respectively. Also, there was a difference in the definition of arrhythmia recurrences used for the clinical endpoint as discussed above. Nevertheless, we did not observe major differences in the HR, and the random-effect model did not reveal significant heterogeneity from our analysis (I2=0.0%). Thirdly, data regarding the adverse event were limited due to the overall low event rates which subsequently limited the power of the analysis.